Literature DB >> 3011243

Antibody-Pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro.

M J Bjorn, G Groetsema, L Scalapino.   

Abstract

Breast tumor selective antibodies (MAB) conjugated to Pseudomonas exotoxin A (PE) formed immunotoxins with potent cytotoxicities for human breast tumor cell lines. The most effective of the MAB-PE conjugates were about 500-fold more toxic to the breast tumor target cell lines than to the nontarget human fibroblast cell line. Specificity of cytotoxicity by MAB-PE conjugates was demonstrated by protection of target cells in the presence of excess unconjugated homologous antibody. A MAB-PE conjugate inhibited protein synthesis more rapidly than the corresponding MAB-ricin toxin A chain (RTA) conjugate. Generally, there was a direct correlation between the cytotoxicity of RTA and PE when conjugated to the same MAB: MABs that made highly cytotoxic RTA conjugates made effective PE conjugates and MABs that made poorly cytotoxic RTA conjugates made PE conjugates of low cytotoxicity; however, one MAB-PE immunotoxin was cytotoxic to the human breast tumor cell lines, whereas the corresponding MAB-RTA immunotoxin was noncytotoxic at the highest dose tested. In contrast to MAB-RTA conjugates, which require a cleavable (disulfide) linkage for maximal in vitro cytotoxicity, MAB-PE conjugates were about equally cytotoxic when linked by either a cleavable or noncleavable (thioether) bond.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011243

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  7 in total

1.  Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.

Authors:  Christopher M Pirie; David V Liu; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2013-07-05       Impact factor: 6.261

Review 2.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.

Authors:  M J Bjorn; H S Smith; S H Dairkee
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.

Authors:  R Orlandi; S Canevari; F P Conde; F Leoni; D Mezzanzanica; M Ripamonti; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 5.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 6.  Bacteriotherapy in Breast Cancer.

Authors:  Atieh Yaghoubi; Majid Khazaei; Seyed Mahdi Hasanian; Amir Avan; William C Cho; Saman Soleimanpour
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

7.  Development of a novel small antibody that retains specificity for tumor targeting.

Authors:  Zi-Peng Zhen; Jie Zhang; Si-Yuan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.